文献速递胸部肿瘤

曲美替尼联合4-甲基伞形酮通过阻断ERK和下调CD44发挥抗肿瘤作用并影响恶性胸膜间皮瘤中的PD-1和PD-L1

Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma.
PubMed 文献 · J Thorac Oncol · 2016-11-17

本研究在体外和体内评估MEK抑制剂曲美替尼与透明质酸合成抑制剂4-甲基伞形酮单用及联用对恶性胸膜间皮瘤细胞的作用。结果显示两药均抑制细胞增殖,曲美替尼浓度依赖性阻断ERK磷酸化并降低CD44表达,4-MU抑制ERK磷酸化但不影响CD44。小鼠异种移植模型中两药单用均较对照抑制肿瘤生长,联用抑制效果强于任一单药。

要点

  • 曲美替尼浓度依赖性阻断MEK依赖的ERK磷酸化并降低CD44表达。
  • 4-MU抑制ERK磷酸化但不降低CD44表达。
  • 小鼠异种移植模型中两药联用的肿瘤抑制效果强于任一单药。

核心结论

  • 作者认为曲美替尼和4-MU是恶性胸膜间皮瘤有前景的治疗药物,值得进一步研究两者联合应用。

研究设计与样本

  • 体外细胞实验联合小鼠异种移植模型的在体研究,评估曲美替尼和4-MU单用及联用对恶性胸膜间皮瘤细胞的作用。
  • 方法包括细胞活力检测、Western blot分析和小鼠异种移植模型。

主要发现

  • 曲美替尼和4-MU在恶性胸膜间皮瘤细胞中均表现出抗增殖活性。
  • 曲美替尼以浓度依赖性方式阻断MEK依赖的细胞外信号调节激酶(ERK)磷酸化并降低CD44表达。
  • 曲美替尼抑制Fra-1(激活蛋白1[AP1]组分)表达、抑制ERK磷酸化并降低CD44表达。
  • 4-MU抑制ERK磷酸化但不降低CD44表达。
  • 小鼠异种移植模型中,曲美替尼和4-MU单用均较对照抑制肿瘤生长,联合用药的抑制效果强于任一单药。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Malignant pleural mesothelioma (MPM) is a highly aggressive malignancy in which the mitogen-activated protein kinase pathway plays a critical role in the regulation of tumorigenesis. Hyaluronic acid (HA) is a major component of the extracellular matrix, and elevated HA levels with a concurrent increase in malignant properties are associated with MPM. METHODS: We evaluated the effects of trametinib, a mitogen-activated protein kinase (MEK) inhibitor, and 4-methylumbelliferone (4-MU), an HA synthesis inhibitor, alone and in combination on MPM cells in vitro and in vivo. We studied the effects of trametinib, 4-MU, and their combination on MPM cells by using cell viability assays, Western blot analysis, and a mouse xenograft model. RESULTS: Trametinib and 4-MU exhibited antiproliferative activity in MPM cells. Trametinib blocked MEK-dependent extracellular signal-regulated kinase (ERK) phosphorylation and decreased CD44 expression in a concentration-dependent manner. Trametinib inhibited the expression of Fra-1 (the activator protein 1 [AP1] component), inhibited ERK phosphorylation, and decreased CD44 expression. 4-MU inhibited ERK phosphorylation but not CD44 expression. In a mouse xenograft model, trametinib and 4-MU alone suppressed tumor growth compared with a control. The combination had a greater inhibitory effect than either monotherapy. Immunohistochemical analysis showed that trametinib treatment alone significantly reduced expression of programmed cell death 1 ligand 1. Furthermore, the combination of trametinib and 4-MU resulted in higher expression of programmed cell death 1 and programmed cell death 1 ligand 1 than did the 4-MU treatment alone. CONCLUSIONS: Our results suggest that trametinib and 4-MU are promising therapeutic agents in MPM and that further study of the combination is warranted.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Cho H, Matsumoto S, Fujita Y, et al. Trametinib plus 4-Methylumbelliferone Exhibits Antitumor Effects by ERK Blockade and CD44 Downregulation and Affects PD-1 and PD-L1 in Malignant Pleural Mesothelioma. J Thorac Oncol. 2016. PMID: 27867002. doi:10.1016/j.jtho.2016.10.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。